assumptions and are designed to represent an upper bound on likely risks. However, several unresolved issues greatly increase uncertainty in a risk assessment involving PAHs (and in risk-based goals) and, more importantly, make it difficult to determine whether risk is being over-or underestimated. Issues related to regulatory toxicology that affect uncertainty in risk estimates include the lack of a dose-response estimate for site-of-contact tumors caused by dermal exposure, questions regarding the accuracy of the available cancer slope factor for oral exposure, and the lack of an adequate approach for addressing the potency of mixtures of PAHs. Factors that affect uncertainty in exposure estimates include questions regarding the effect of the environmental matrix on the availability of the chemicals to a biological receptor and the lack of information on levels of those PAHs that are not detected using standard analytical procedures. A consideration of these issues is critical to defining the risk posed by PAHs at hazardous waste sites. These unresolved issues and their potential influence on risk assessment results are described here. In addition, cleanup goals Mrly equivuienty1 ratr .1 mSvse n-aw"" for PAHs based on a consideration of both health risks and practicality are proposed. (12) would mean that the current cancer slope factor for BaP is too low by a factor of 5. EPA has revised the cancer slope factor for oral exposure to BaP to a value of 7.3 (mg/kg/day)Yi (13) . This value is the geometric mean of values from three analyses of the Neal and Rigdon data and one analysis of a study by Brune et al. (14) . All cancer slope factors from these four analyses were within a range of 4.5-9.0 (mg/kg/day)Y. The Brune et al. (14) study lasted 2 years, and consequently, no adjustment for length of lifetime was necessary. However, this study by itself is probably insufficient to prove that a Kvalue of 3 is appropriate for the Neal and Rigdon (9) study or that a cancer slope factor of around 7 (mg/kg/day)Y', and not 35 or 800 (mg/kg/day)Y (the cancer slope factor associated with a Kvalue of 4 or 6, respectively), is appropriate for BaP.
EPA has established an approach for calculating preliminary remediation goals (PRGs) for residential exposure via soil ingestion (15 BaP and other carcinogenic PAHs produce skin tumors at the site of contact in mice at very low doses, and evidence suggests that materials containing these compounds are also skin carcinogens for humans (16) . The primary route of exposure to PAHs at many hazardous waste sites is likely to be direct dermal contact. There is currently no estimate of the dose-response relationship between dermal exposure and site-of-contact cancer, and this route of exposure is therefore not considered in setting remediation goals such as those listed in Table 1 .
Sullivan et al. (17) estimated a dermal site-of-contact cancer slope factor for BaP of 6.6 x 103 (mg/cm2/day)-' based on data from a mouse skin-painting bioassay. This value is somewhat questionable because the doses used in the skin-painting study produced over 90% tumor response, and results presented in Clement (18) indicate that at these response levels, a very poor curve fit is achieved (19) . Based on discussions with the author of the skin-painting study, Sullivan et al. (17) assumed that the exposed area of the mouse back was 30 cm and that three weekly skin-painting applications led to exposure for 3/7 of a week, or, in other words, that the BaP stays on the skin for 24 hr after application. Using these assumptions, a linearized multistage model (GLOBAL82), and data collected by Schmahl et al. (20) (18, 19, 22) . These TEFs indicate the carcinogenic potency of each compound relative to BaP, and multiplying the concentration of each PAH by the TEF yields a concentration for the total PAH mixture that is expressed in terms of an equivalent concentration (with regard to toxic potency) of BaP, called BaP equivalents (BaPe uiv). Table 3 presents the TEFs   developed by the various researchers, and  Table 4 indicates the BaP equivalent concentrations determined using the historical EPA approach, the current EPA approach (22) , and the Nisbet and LaGoy (19) approach on some PAH data from a coaltar-contaminated soil sample (23 (3, 7) . Based on the data reviewed by Menzie et (24, 25) .
Research to address some of the issues raised in this article (e.g., oral cancer slope factors; the effect of mixtures) is underway in both government and private laboratories. However, much work remains to be done, particularly in the areas of determining an appropriate dermal site-of-contact slope factor, evaluating the effects of unanalyzed compounds, and in assessing the bioavailability of PAHs from environmental media. m -9 --9 .9
